Grufity logoGrufity logo

Inovio Pharmaceuticals Inc Stock Research

INO

0.96USD+0.01(+1.05%)Market Closed

Market Summary

USD0.96+0.01
Market Closed
1.05%

INO Stock Price

INO RSI Chart

INO Valuation

Market Cap

239.4M

Price/Earnings (Trailing)

-0.86

Price/Sales (Trailing)

23.33

EV/EBITDA

-0.71

Price/Free Cashflow

-1.1

INO Price/Sales (Trailing)

INO Profitability

EBT Margin

-2705.57%

Return on Equity

-125.84%

Return on Assets

-80.28%

Free Cashflow Yield

-90.73%

INO Fundamentals

INO Revenue

Revenue (TTM)

10.3M

Revenue Y/Y

-85.14%

Revenue Q/Q

-98.64%

INO Earnings

Earnings (TTM)

-279.8M

Earnings Y/Y

49.07%

Earnings Q/Q

-44.14%

Price Action

52 Week Range

0.954.00
(Low)(High)

Last 7 days

-15.0%

Last 30 days

-31.9%

Last 90 days

-37.2%

Trailing 12 Months

-73.7%

INO Financial Health

Current Ratio

3.25

INO Investor Care

Shares Dilution (1Y)

18.57%

Diluted EPS (TTM)

-1.17

Peers (Alternatives to Inovio Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
298.1B
1.4B
-4.03% 17.35%
-148.75
210.51
20.37% -37.45%
275.1B
58.1B
2.18% 0.81%
23.24
4.74
3.30% 2.55%
85.3B
12.2B
6.89% 19.23%
19.66
7.01
-24.26% -46.28%
77.6B
8.9B
3.23% 21.68%
23.36
8.69
17.91% 41.84%
23.5B
1.0B
-5.08% 16.85%
-20.78
22.66
22.88% -32.64%
11.2B
933.0M
4.06% 58.34%
-15.86
11.96
32.93% -67.99%
9.9B
1.9B
-15.84% 20.83%
13.6
5.11
14.88% 52.86%
MID-CAP
2.6B
363.3M
-18.31% -45.95%
-3.69
7.18
3.39% -55.81%
2.2B
12.4M
-14.38% -52.88%
-3.03
180.64
- -27.34%
SMALL-CAP
960.5M
1.0B
17.43% -62.90%
-2.92
0.96
-43.42% -989.45%
408.6M
152.4M
-10.15% 6.80%
-25.95
2.68
5.37% -174.76%
239.4M
10.3M
-31.91% -73.70%
-0.86
23.33
478.23% 7.85%
87.4M
-
-7.38% -53.06%
-3.6
-
- -4.49%
3.3M
23.8M
-29.85% -97.83%
-0.05
0.14
-17.54% -36.25%

Financials for Inovio Pharmaceuticals

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-10.9%10,262,26811,520,7292,658,2942,728,7381,774,758
Operating Expenses-15.3%277,835,788328,112,421343,446,096321,999,134302,992,677
  S&GA Expenses-0.1%90,185,28590,282,97691,615,11255,824,61753,752,353
  R&D Expenses-21.1%187,650,503237,829,445251,830,984266,174,517249,240,324
EBITDA16.1%-272,698,900-324,994,644-347,390,313-321,119,402-
EBITDA Margin5.8%-26.57-28.21-216-191-
Earnings Before Taxes15.9%-277,652,852-330,137,293-352,522,438-326,165,085-303,224,323
EBT Margin5.6%-27.06-28.66-219-194-
Interest Expenses-11.7%1,253,9521,420,7771,583,6631,736,9011,936,447
Net Income15.8%-279,818,065-332,302,506-354,687,651-328,330,298-303,658,710
Net Income Margin5.5%-27.27-28.84-221-196-
Free Cahsflow0.9%-217,184,574-219,214,254-198,321,425-225,743,381-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-11.1%349392459446496
  Current Assets-10.0%315350416400448
    Cash Equivalents110.7%46.0022.0041.0059.0071.00
  Net PPE-50.4%8.0016.0016.0017.0017.00
  Goodwill0%11.0011.0011.0011.0011.00
Liabilities0.7%12612516290.0096.00
  Current Liabilities2.1%97.0095.0013159.0066.00
Shareholder's Equity-16.6%222267298355400
  Retained Earnings-3.8%-1,487-1,433-1,395-1,300-1,209
  Additional Paid-In Capital0.6%1,7111,7011,6941,6421,610
Shares Outstanding6.0%249235219217-
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations0.7%-216-217-196-224-215
  Share Based Compensation-8.9%23.0025.0027.0024.0026.00
Cashflow From Investing123.2%11049.0060.00121-175
Cashflow From Financing-33.3%82.0012311979.00211

Risks for INO

What is the probability of a big loss on INO?

100%


Probability that Inovio Pharmaceuticals stock will be more than 20% underwater in next one year

97.3%


Probability that Inovio Pharmaceuticals stock will be more than 30% underwater in next one year.

86.9%


Probability that Inovio Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does INO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Inovio Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for INO

Cumulative Returns on INO

-20.0%


10-Year Cumulative Returns

-26%


7-Year Cumulative Returns

-27.4%


5-Year Cumulative Returns

-47.5%


3-Year Cumulative Returns

What are the long-term rolling returns for INO?

FIve years rolling returns for Inovio Pharmaceuticals.

Annualized Returns

Which funds bought or sold INO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-0.05
-4,727
43,273
-%
2023-03-06
Rockefeller Capital Management L.P.
unchanged
-
-
1,000
-%
2023-03-03
TIAA, FSB
unchanged
-
-2,617
22,383
-%
2023-02-28
Voya Investment Management LLC
reduced
-90.97
-1,635,660
145,345
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-100
-14,000
-
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
reduced
-99.63
-15,945
55.00
-%
2023-02-17
Compass Wealth Management LLC
new
-
265
265
-%
2023-02-16
American Trust
new
-
43,159
43,159
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
added
60.94
482
482
-%
2023-02-15
Financial Advocates Investment Management
sold off
-100
-628,000
-
-%

1–10 of 46

Latest Funds Activity

Are funds buying INO calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own INO
No. of Funds

Inovio Pharmaceuticals News

The DBT News

Inovio Pharmaceuticals Inc. [INO] Is Currently -8.20 below its 200 ....

The DBT News,
89 minutes ago

InvestorsObserver

DirectorsTalk Interviews

The Motley Fool

Schedule 13G FIlings of Inovio Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
state street corp
12.61%
31,472,352
SC 13G/A
Feb 09, 2023
vanguard group inc
6.83%
17,042,500
SC 13G/A
Jan 24, 2023
blackrock inc.
9.3%
23,284,119
SC 13G/A
Apr 11, 2022
state street corp
10.49%
23,267,928
SC 13G/A
Feb 11, 2022
state street corp
6.32%
13,300,430
SC 13G/A
Feb 01, 2022
blackrock inc.
8.7%
18,244,914
SC 13G/A
Feb 11, 2021
nikko asset management americas, inc.
0%
0
SC 13G/A
Feb 11, 2021
wasatch advisors inc
-
0
SC 13G/A
Feb 10, 2021
vanguard group inc
5.42%
9,185,639
SC 13G/A
Feb 10, 2021
state street corp
5.25%
8,894,555
SC 13G

INO Fair Value

Inovio Pharmaceuticals fair value in different scenarios

The table shows the Fair Value estimates for Inovio Pharmaceuticals for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

0.26

-72.92%

0.26

-72.92%

0.26

-72.92%

0.26

-72.92%

0.27

-71.88%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Inovio Pharmaceuticals Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Inovio Pharmaceuticals

View All Filings
Date Filed Form Type Document
Mar 13, 2023
4
Insider Trading
Mar 13, 2023
4
Insider Trading
Mar 13, 2023
4
Insider Trading
Mar 13, 2023
4
Insider Trading
Mar 01, 2023
10-K
Annual Report
Mar 01, 2023
8-K
Current Report
Mar 01, 2023
POS AM
POS AM
Mar 01, 2023
POSASR
POSASR
Feb 28, 2023
4
Insider Trading
Feb 28, 2023
4
Insider Trading

Latest Insider Trading transactions for INO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-13
Weiner David B.
sold
-6,707
1.15
-5,833
-
2023-03-11
Weiner David B.
acquired
-
-
11,666
-
2023-03-11
Humeau Laurent
acquired
-
-
59,737
chief scientific officer
2023-03-11
KIES PETER
acquired
-
-
59,737
cfo
2023-03-11
KIES PETER
sold (taxes)
-35,493
1.13
-31,410
cfo
2023-03-11
Shea Jacqueline Elizabeth
sold (taxes)
-29,357
1.13
-25,980
chief executive officer
2023-03-11
Humeau Laurent
sold (taxes)
-23,343
1.13
-20,658
chief scientific officer
2023-03-11
Shea Jacqueline Elizabeth
acquired
-
-
59,737
chief executive officer
2023-02-27
Weiner David B.
sold
-14,935
1.28
-11,668
-
2023-02-26
Humeau Laurent
sold (taxes)
-35,759
1.28
-27,937
chief scientific officer

1–10 of 50

Jacqueline E. Shea
320
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

INO Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues [Abstract]   
Revenue from collaborative arrangements and other contracts, including affiliated entity$ 10,262,268$ 1,774,758$ 7,411,220
Operating expenses:   
Research and development187,650,503249,240,32494,245,436
General and administrative90,185,28553,752,35337,247,828
Total operating expenses277,835,788302,992,677131,493,264
Loss from operations(267,573,520)(301,217,919)(124,082,044)
Other income (expense):   
Interest income4,782,0303,363,0803,311,846
Interest expense(1,253,952)(1,936,447)(8,702,450)
Change in fair value of derivative liability00(75,670,977)
(Loss) gain on investment in affiliated entities(1,899,654)(553,570)36,556,658
Net unrealized (loss) gain on available-for-sale equity securities(7,846,172)(3,222,838)1,695,497
Other (expense) income, net(3,861,584)343,371(704,896)
Gain on deconsolidation of Geneos004,121,075
Net loss before share in net loss of Geneos(277,652,852)(303,224,323)(162,890,304)
Share in net loss of Geneos(2,165,213)(434,387)(4,584,610)
Net loss(279,818,065)(303,658,710)(167,474,914)
Net loss attributable to non-controlling interest001,063,757
Net loss attributable to Inovio Pharmaceuticals, Inc.$ (279,818,065)$ (303,658,710)$ (166,411,157)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders   
Basic (in dollars per share)$ (1.17)$ (1.45)$ (1.07)
Diluted (in dollars per share)$ (1.17)$ (1.45)$ (1.07)
Weighted average number of common shares outstanding   
Basic (in shares)238,622,188208,829,801155,126,857
Diluted (in shares)238,622,188208,829,801155,126,857
Convertible Bonds   
Other income (expense):   
Gain (loss) on extinguishment of convertible bonds and senior notes$ 0$ 0$ (8,177,043)
6.50% Convertible Senior Notes Due 2024   
Other income (expense):   
Gain (loss) on extinguishment of convertible bonds and senior notes$ 0$ 0$ 8,762,030

INO Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 46,329,359$ 71,143,778
Short-term investments206,669,397330,170,940
Accounts receivable1,701,7265,466,850
Accounts receivable from affiliated entities10,036,4902,565,194
Prepaid expenses and other current assets50,130,48138,836,991
Prepaid expenses and other current assets from affiliated entities375,227261,192
Total current assets315,242,680448,444,945
Fixed assets, net7,727,99717,453,206
Investments in affiliated entity2,007,1423,906,796
Intangible assets, net2,129,8612,626,355
Goodwill10,513,37110,513,371
Operating lease right-of-use assets10,228,20711,571,026
Other assets684,0441,425,794
Total assets348,533,302495,941,493
Current liabilities:  
Accounts payable and accrued expenses79,686,88547,644,530
Accounts payable and accrued expenses due to affiliated entities1,220,439548,032
Accrued clinical trial expenses10,594,07310,326,266
Deferred revenue021,628
Operating lease liability2,803,9732,603,956
Grant funding liability2,475,0314,559,721
Grant funding liability from affiliated entities87,67337,500
Total current liabilities96,868,07465,741,633
Deferred revenue, net of current portion064,361
Operating lease liability, net of current portion12,655,58615,459,559
Deferred tax liabilities32,04632,046
Other liabilities014,826
Total liabilities126,170,54696,272,072
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:  
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2022 and 202100
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2022 and 2021, issued and outstanding: 253,091,319 at December 31, 2022 and 217,382,887 at December 31, 2021253,090217,382
Additional paid-in capital1,710,656,1911,609,589,797
Accumulated deficit(1,487,847,784)(1,209,855,522)
Accumulated other comprehensive loss(698,741)(282,236)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity222,362,756399,669,421
Total liabilities and stockholders’ equity348,533,302495,941,493
6.50% Convertible Senior Notes Due 2024  
Current liabilities:  
Convertible senior notes$ 16,614,840$ 14,959,647